Diaceutics
Precision medicine diagnostic commercialization and data platform.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor | €0.0 | round |
| investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor | €0.0 Valuation: €0.0 6.7x EV/Revenue 150.2x EV/EBITDA | round | |
* | £1.0m | Grant | |
| Total Funding | 000k | ||
| GBP | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | 10 % | 40 % | 22 % | 36 % | 24 % | 24 % | 19 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | 17 % | 19 % | 10 % | 9 % | 18 % | 22 % | 25 % |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | 4 % | 4 % | (7 %) | (5 %) | 3 % | 7 % | 13 % |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article, Equity research estimates
Related Content
Diaceutics PLC provides data analytics, technology, and commercialization solutions to the pharmaceutical and biotechnology industries. Founded in 2005 by Peter Keeling, the company is headquartered in Belfast, Northern Ireland. Keeling envisioned a healthcare system where diagnostics were central to treatment, aiming to solve inefficiencies in patient testing for precision medicines. The company went public on the AIM market of the London Stock Exchange in 2019 to fund further growth.
The company's core offering is the DXRX platform, described as the world's first diagnostic network for precision medicine. DXRX connects pharmaceutical companies, laboratories, and physicians, integrating real-world diagnostic testing data from a global network of over 2,500 labs. This platform enables pharma clients to overcome hurdles in diagnostic testing, optimize the launch of new therapies, and improve the return on investment for their precision medicine drugs. Diaceutics' business model is based on providing these end-to-end commercialization solutions, which include data analytics, scientific and advisory services, and implementation support. Revenue is generated through these services, with a significant portion being recurring. The company serves the world's leading pharmaceutical companies, working with 21 of the top 30 global pharma firms.
The DXRX platform provides clients with access to a vast repository of anonymized patient data, laboratory data, and insurance claims data to inform diagnostic testing strategies. In March 2024, Diaceutics announced a significant upgrade to the platform, incorporating generative AI and new US data sets, including social determinants of health, to enhance its analytical capabilities. The company has also expanded its services to include Pathology Engagement Liaisons (PEL) to improve education and engagement with pathologists for specific cancer types like pancreatic cancer.
Keywords: precision medicine, diagnostic commercialization, DXRX platform, pharmaceutical services, data analytics, biotech, diagnostic testing, patient data, laboratory network, real-world data, biomarker testing, oncology, therapy launch, drug development, health technology, pathology engagement, data insights, pharma solutions, diagnostic strategy, clinical data